Assessing correlates of protection in vaccine trials: statistical solutions in the context of high vaccine efficacy
Abstract Background The use of correlates of protection (CoPs) in vaccination trials offers significant advantages as useful clinical endpoint substitutes. Vaccines with very high vaccine efficacy (VE) are documented in the literature (VE ≥95%). The rare events (number of infections) observed in the...
Main Authors: | Andrea Callegaro, Fabian Tibaldi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-03-01
|
Series: | BMC Medical Research Methodology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12874-019-0687-y |
Similar Items
-
Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpoints
by: Wenbo Zhu, et al.
Published: (2017-09-01) -
Foundations for improved vaccine correlate of risk analysis using positive-unlabeled learning
by: Natasha S. Kelkar, et al.
Published: (2023-01-01) -
Surrogate endpoints in trials: a call for better reporting
by: Oriana Ciani, et al.
Published: (2022-12-01) -
Pre-existing chikungunya virus neutralizing antibodies correlate with risk of symptomatic infection and subclinical seroconversion in a Philippine cohort
by: In-Kyu Yoon, et al.
Published: (2020-06-01) -
A comparison of the test-negative and the matched case-control study designs for estimation of EV71 vaccine immunological surrogate endpoints from a randomized controlled trial
by: Li Zhang, et al.
Published: (2022-11-01)